Redx Pharma has quickly established itself as one of the largest biotechnology companies in Europe, focused on the development of a wide range of early stage, proprietary small molecule therapeutics to address high unmet medical needs in cancer and infectious disease.
Redx Pharma and Pierre Fabre Laboratories have today completed a collaboration and option agreement in cancer research.
The exclusive deal will see Redx and Pierre Fabre Research Institute (IRPF) work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.
The financial terms of the agreement have not been disclosed but Redx Pharma chief executive Neil Murray described the deal as
a highly significant milestone in the company's development.
A major one day conference looking at the critical issues relating to the development of new anti-infectives and the problem of drug resistance.
Alderley Park Conference Centre, 26/11/13
Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.
Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.
Finding new intellectual property that supports development of novel agrochemicals with shorter, less costly development cycles.